Breaking News Instant updates and real-time market news.

AAPL

Apple

$209.08

1.08 (0.52%)

, FB

Facebook

$185.70

7.94 (4.47%)

06:18
08/07/18
08/07
06:18
08/07/18
06:18

Consumer Reports names Apple Pay Cash as top P2P payments service

Consumer Reports compared five different platforms in the publication's first evaluation of mobile person-to-person payment systems, with Apple Pay Cash (AAPL) emerging the victor over segment rivals including Venmo, Zella, Facebook (FB) P2P Payments in Messenger and Square Cash (SQ). Consumer Reports, which considered security, privacy, support, and more in the process, said "Apple's overall rating was significantly higher than for the other services." The publication found Apple Pay Cash earned the highest marks for security and privacy and its biggest demerit was the lack of broad availability. CR found Venmo, Cash App and Facebook P2P Payments in Messenger to be "very good performers" for those who don't use Apple products, but they received only fair scores for data privacy. Reference Link

AAPL

Apple

$209.08

1.08 (0.52%)

FB

Facebook

$185.70

7.94 (4.47%)

SQ

Square

$70.90

2.54 (3.72%)

  • 13

    Aug

  • 14

    Aug

  • 15

    Aug

  • 16

    Aug

  • 28

    Aug

  • 12

    Sep

AAPL Apple
$209.08

1.08 (0.52%)

08/02/18
SBSH
08/02/18
NO CHANGE
Target $5
SBSH
Sell
Citi reiterates Sell on Fitbit, says not an acquisition target
Citi analyst Jim Suva reiterates a Sell rating on Fitbit (FIT) with a $5 price target following the company's Q2 results, which he notes were largely better than expected except for a decline in free cash flow. Apple's (AAPL) smart watch is smarter than Fitbit's (FIT) smartwatches, which do not allow "robust" two-way communication or a lengthy app catalog, and the price differential is immaterial, Suva tells investors in a post-earnings research note. Further, he does not see Fitbit as an acquisition target.
08/01/18
BTIG
08/01/18
NO CHANGE
Target $235
BTIG
Buy
Apple price target raised to $235 from $207 at BTIG
BTIG analyst Walter Piecyk, in a note published last night, raised his price target on Apple (AAPL) shares to $235 from $207, stating that he believes there are early signs that upgrade rates might be bottoming and noting that iPhone revenue grew by over 20% despite "historic low" upgrade rates in Q3. Apple CEO Tim Cook hinted at a noteworthy content project, added Piecyk, who agrees with fellow BTIG analyst Rich Greenfield's view that Apple is likely to follow Netflix (NFLX) and Amazon's (AMZN) approach "build their way into the market rather than buy their way in" to video. Piecyk keeps a Buy rating on Apple shares.
08/01/18
BMOC
08/01/18
NO CHANGE
Target $199
BMOC
Market Perform
Apple price target raised to $199 from $184 at BMO Capital
BMO Capital analyst Tim Long raised his price target on Apple to $199 after its Q3 earnings beat and raise of its guidance, saying the results were driven by "better than seasonal" iPhone selling prices and strong Services segment. The analyst notes that ASPs declined about 8% in Q3 over the past two years, but only saw a 1% sequential decline this time. Long also keeps his Market Perform rating on Apple, saying the upside in the shares is limited because of valuation.
08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
FB Facebook
$185.70

7.94 (4.47%)

08/06/18
STFL
08/06/18
NO CHANGE
Target $202
STFL
Buy
Facebook added to Stifel Select List, Amazon removed
Stifel analyst Scott Devitt replaced Amazon (AMZN) with Facebook (FB) on the Stifel Select List, citing the strong year-to-date performance of Amazon shares, which he still likes and keeps a Buy rating upon. He believes Facebook expectations, and the shares, are appropriately set to allow for longer-term outperformance given the material reset that followed the company's "painful" Q2 update, Devitt tells investors. He maintains a Buy rating and $202 price target on Facebook.
07/30/18
MZHO
07/30/18
NO CHANGE
Target $25
MZHO
Underperform
Twitter should trade at discount to Facebook, says Mizuho
Mizuho analyst James Lee says that while Twitter (TWTR) reported "strong" Q2 results, EBITDA and implied revenue guidance for Q3 was below consensus by 16% and 6%, respectively. Management cited the health initiative that will slow down active user growth and increase operating expenditures due to headcount additions, Lee tells investors in a post-earnings research note. He keeps an Underperform rating on Twitter shares with a $25 price target, which represents 12.5 times his 2020 EBITDA estimate. The analyst believes the stock should trade at a discount to his Facebook (FB) target of 13.5 times EBITDA.
08/02/18
MKMP
08/02/18
NO CHANGE
Target $230
MKMP
Buy
Facebook price target lowered to $230 from $255 at MKM Partners
MKM Partners analyst Rob Sanderson lowered his price target on Facebook to $230 but kept his Buy rating, saying investors should "take advantage" of the "second capitulation" in the stock. The analyst says the current valuation multiple is too low after the management's "aggressively conservative" outlook relative to consensus even though growth deceleration is nearing, with consensus pricing in about 15% of revenue slowdown in the next two quarters.
SQ Square
$70.90

2.54 (3.72%)

08/06/18
08/06/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. INTERCEPT DOUBLE UPGRADED AT GOLDMAN: Goldman Sachs analyst Salveen Richter double upgraded Intercept Pharmaceuticals (ICPT) to Buy from Sell and raised his price target for the shares to $157 from $46. The analyst said Ocaliva in fatty liver disease nonalcoholic steatohepatitis is the crux of Intercept's value proposition and that he's positive into the Phase 3 Regenerate interim readout in the first half of 2019. Intercept should benefit from Ocaliva's global first-mover advantage in NASH, Richter said. In late morning trading, Intercept shares are up 12%. BUCKINGHAM UPGRADES SQUARE TO BUY: Buckingham upgraded Square (SQ) to Buy from Neutral and raised its price target to $85 from $65. Analyst Chris Brendler said the strong Q2 results reduced his concerns about high valuation and competition and said there is no reason why Square will not continue to report better then expected core revenue growth into 2020. Brendler said long-run adjusted EBITDA margins of 40%-50% justify a higher valuation. PIPER CUTS ACADIA TO NEUTRAL: Piper Jaffray analyst Danielle Brill downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Overweight and cut her firm's price target on shares to $19 from $61 after taking over coverage of the name. The recent negative headlines related to potential Nuplazid safety issues will continue to weigh on sales and the shares for the foreseeable future, Brill said. Further, the analyst does not have a high level of conviction for positive data from Acadia's near-term catalysts, namely the Phase 2 major depressive disorder data in September and the Phase 2 negative schizophrenia symptoms readout in the first half of 2019. BARCLAYS CUTS INTEL TO EQUAL WEIGHT: Barclays analyst Blayne Curtis downgraded Intel (INTC) to Equal Weight from Overweight and cut his price target for the shares to $53 from $62. The analyst believes upside in the shares will be challenging until the company's margins bottom. JEFFERIES SAYS OHIO INCIDENT NOT A RISK TO CHIPOTLE TRAFFIC: After analyzing digital engagement with the brand from last week and compared to the Virginia incident last July, Jefferies analyst Andy Barish does not believe the illnesses at the Ohio restaurant put Chipotle Mexican Grill's (CMG) traffic trends at risk. The analyst believes Chipotle's procedures were followed in Ohio, the number of cases was not substantiated, and the company did a better job controlling the narrative and taking action. Barish kept a Buy rating on Chipotle shares with a $550 price target.
08/06/18
08/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Comcast (CMCSA) upgraded to Overweight from Neutral at Atlantic Equities with analyst Hamilton Faber saying he believes "the bulk of the M&A storm" has passed. 2. Qualcomm (QCOM) upgraded to Outperform from Market Perform at Cowen with analyst Matthew Ramsay citing the company's $30B buyback and saying he believes the shares offer a compelling risk/reward with effects of lower spending, solid customer performance, and potential QTL resolutions. 3. Square (SQ) upgraded to Buy from Neutral at Buckingham with analyst Chris Brendler saying the Q2 strong results reduced his concerns about high valuation and competition and said there is no reason why Square will not continue to report better-then-expected core revenue growth into 2020. 4. Parker-Hannifin (PH) upgraded to Outperform from In Line at Evercore ISI with analyst David Raso saying the company's recent operational struggles are behind it with this quarters report and views 2019 guidance as conservative. 5. Intercept (ICPT) upgraded to Buy from Sell at Goldman Sachs with analyst Salveen Richter saying Ocaliva in fatty liver disease nonalcoholic steatohepatitis is the crux of Intercept's value proposition and that he's positive into the Phase 3 Regenerate interim readout in the first half of 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/06/18
BUCK
08/06/18
UPGRADE
Target $42
BUCK
Buy
Square upgraded to Buy on revenue acceleration at Buckingham
As previously reported, Buckingham upgraded Square to Buy from Neutral and raised its price target to $85 from $65. Analyst Chris Brendler said the Q2 strong results reduced his concerns about high valuation and competition and said there is no reason why Square will not continue to report better-then-expected core revenue growth into 2020. Brendler said long-run adjusted EBITDA margins of 40-50% justify a higher valuation.

TODAY'S FREE FLY STORIES

CR

Crane

$80.55

-0.18 (-0.22%)

, CIR

Circor

$45.77

-0.03 (-0.07%)

06:32
06/25/19
06/25
06:32
06/25/19
06:32
Hot Stocks
Crane refutes Circor's plan, urges shareholders to tender shares »

Crane (CR) filed a…

CR

Crane

$80.55

-0.18 (-0.22%)

CIR

Circor

$45.77

-0.03 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

AGN

Allergan

$129.65

-1.32 (-1.01%)

, ABBV

AbbVie

$78.41

-0.37 (-0.47%)

06:28
06/25/19
06/25
06:28
06/25/19
06:28
Periodicals
Breaking Periodicals news story on Allergan, AbbVie »

AbbVie would pay $188 per…

AGN

Allergan

$129.65

-1.32 (-1.01%)

ABBV

AbbVie

$78.41

-0.37 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

AGN

Allergan

$129.65

-1.32 (-1.01%)

, ABBV

AbbVie

$78.41

-0.37 (-0.47%)

06:27
06/25/19
06/25
06:27
06/25/19
06:27
Periodicals
Breaking Periodicals news story on Allergan, AbbVie »

AbbVie near deal to…

AGN

Allergan

$129.65

-1.32 (-1.01%)

ABBV

AbbVie

$78.41

-0.37 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

PT

Pintec Technology

$2.98

-0.13 (-4.18%)

06:27
06/25/19
06/25
06:27
06/25/19
06:27
Hot Stocks
Pintec Technology announces strategic partnership with Bank of Ganzhou »

Pintec Technology inked a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDY

Dr. Reddy's

$36.08

-0.12 (-0.33%)

06:24
06/25/19
06/25
06:24
06/25/19
06:24
Hot Stocks
Dr. Reddy's launches its Tobramycin Inhalation Solution »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$28.91

-0.17 (-0.58%)

06:21
06/25/19
06/25
06:21
06/25/19
06:21
Periodicals
JD.com's logistics unit raises $218M investment fund, Reuters reports »

The logistics division of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOP

Shopify

$311.63

-15.05 (-4.61%)

06:19
06/25/19
06/25
06:19
06/25/19
06:19
Downgrade
Shopify rating change  »

Shopify downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

CBMG

Cellular Biomedicine

$15.01

(0.00%)

06:19
06/25/19
06/25
06:19
06/25/19
06:19
Initiation
Cellular Biomedicine initiated  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$47.63

0.17 (0.36%)

06:18
06/25/19
06/25
06:18
06/25/19
06:18
Periodicals
Intel plans to cut desktop processor prices by up to 15%, DigiTimes reports »

Intel is planning to cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 25

    Jul

LMT

Lockheed Martin

$359.98

0.555 (0.15%)

06:15
06/25/19
06/25
06:15
06/25/19
06:15
Periodicals
U.S.: Turkey would lose F-35 if Russia arms deal moves forward, Reuters says »

The U.S. cannot allow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

06:12
06/25/19
06/25
06:12
06/25/19
06:12
Periodicals
Nissan overhauls board following disorderly investor meeting, WSJ reports »

Nissan investors voted to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVTL

Pivotal Software

$11.35

-0.15 (-1.30%)

06:11
06/25/19
06/25
06:11
06/25/19
06:11
Downgrade
Pivotal Software rating change  »

Pivotal Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jul

GOOG

Alphabet

$1,115.75

-6.63 (-0.59%)

, GOOGL

Alphabet Class A

$1,117.00

-8.17 (-0.73%)

06:08
06/25/19
06/25
06:08
06/25/19
06:08
Periodicals
Alphabet's Sidewalk Labs meets resistance over Toronto plans, WSJ reports »

Sidewalk Labs, a unit of…

GOOG

Alphabet

$1,115.75

-6.63 (-0.59%)

GOOGL

Alphabet Class A

$1,117.00

-8.17 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 25

    Jul

  • 25

    Jul

  • 27

    Oct

LEN

Lennar

$51.41

0.09 (0.18%)

06:07
06/25/19
06/25
06:07
06/25/19
06:07
Earnings
Lennar reports Q2 EPS $1.30, consensus $1.14 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 28

    Jun

BAS

Basic Energy

$2.43

-0.21 (-7.95%)

06:07
06/25/19
06/25
06:07
06/25/19
06:07
Downgrade
Basic Energy rating change  »

Basic Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

FTSI

FTS International

$5.77

-0.5 (-7.97%)

06:06
06/25/19
06/25
06:06
06/25/19
06:06
Downgrade
FTS International rating change  »

FTS International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMRN

Immuron

$3.00

-0.09 (-2.91%)

06:05
06/25/19
06/25
06:05
06/25/19
06:05
Hot Stocks
Immuron Directors increase shareholdings in the company »

Immuron wishes to advise…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USWS

U.S. Well Services

$5.18

-0.38 (-6.83%)

06:05
06/25/19
06/25
06:05
06/25/19
06:05
Hot Stocks
U.S. Well Services signs agreement with AmeriMex Motor & Controls »

U.S. Well Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMCR

Amcor

$11.14

0.12 (1.09%)

06:03
06/25/19
06/25
06:03
06/25/19
06:03
Hot Stocks
Amcor enters into $394M agreement for sale of three flexible packaging plants »

Amcor announces it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$15.38

0.15 (0.98%)

06:03
06/25/19
06/25
06:03
06/25/19
06:03
Hot Stocks
Rice Team urges EQT Corporation shareholders to vote for Rice Team nominees »

The Rice Team,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

PLL

Piedmont Lithium

$11.50

(0.00%)

06:03
06/25/19
06/25
06:03
06/25/19
06:03
Hot Stocks
Piedmont Lithium announces 47% increase in Piedmont mineral resource estimate »

Piedmont Lithium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GEN

Genesis Healthcare

$1.23

0.01 (0.82%)

06:03
06/25/19
06/25
06:03
06/25/19
06:03
Periodicals
HUD-backed nursing homes have 'serious deficiencies,' NY Times reports »

Dozens of nursing homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

VKTX

Viking Therapeutics

$7.94

-0.07 (-0.87%)

06:02
06/25/19
06/25
06:02
06/25/19
06:02
Initiation
Viking Therapeutics initiated  »

Viking Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

CTRP

Ctrip

$36.43

0.37 (1.03%)

06:00
06/25/19
06/25
06:00
06/25/19
06:00
Hot Stocks
Ctrip enters strategic partnership with Tourism Fiji »

Ctrip has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDGL

Madrigal Pharmaceuticals

$101.39

-3.73 (-3.55%)

, VKTX

Viking Therapeutics

$7.94

-0.07 (-0.87%)

05:58
06/25/19
06/25
05:58
06/25/19
05:58
Initiation
Madrigal Pharmaceuticals, Viking Therapeutics, Genfit initiated  »

Madrigal Pharmaceuticals…

MDGL

Madrigal Pharmaceuticals

$101.39

-3.73 (-3.55%)

VKTX

Viking Therapeutics

$7.94

-0.07 (-0.87%)

GNFT

Genfit

$20.19

-0.02 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.